Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
Novant Health Heart and Vascular Institute
mi
from
Charlotte, NC
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
Novant Health Heart and Vascular Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
NC Heart and Vascular Research
mi
from
Raleigh, NC
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
NC Heart and Vascular Research
mi
from
Raleigh, NC
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
Integris Baptist Medical Center
mi
from
Oklahoma City, OK
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
Integris Baptist Medical Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
Presbyterian University Hospital
mi
from
Pittsburgh, PA
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
Presbyterian University Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
Palmetto Health
mi
from
Columbia, SC
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
Palmetto Health
mi
from
Columbia, SC
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
St. Francis Physician Services Inc., DBA Upstate Cardiology
mi
from
Greenville, SC
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
St. Francis Physician Services Inc., DBA Upstate Cardiology
mi
from
Greenville, SC
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
Seton Heart Institute
mi
from
Austin, TX
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
Seton Heart Institute
mi
from
Austin, TX
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
Methodist Hospital Dallas
mi
from
Dallas, TX
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
Methodist Hospital Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
VA North Texas Health Care System
mi
from
Dallas, TX
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
VA North Texas Health Care System
mi
from
Dallas, TX
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
Plaza Medical Center of Forth Worth
mi
from
Fort Worth, TX
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
Plaza Medical Center of Forth Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
St. Luke's Episcopal Hospital
mi
from
Houston, TX
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
St. Luke's Episcopal Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
Christus Santa Rosa Hospital-City Center
mi
from
New Braunfels, TX
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
Christus Santa Rosa Hospital-City Center
mi
from
New Braunfels, TX
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
University of Vermont Medical Center
mi
from
Burlington, VT
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
University of Vermont Medical Center
mi
from
Burlington, VT
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
Virginia Mason
mi
from
Seattle, WA
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
Virginia Mason
mi
from
Seattle, WA
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
Cardiac Study Center
mi
from
Tacoma, WA
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
Cardiac Study Center
mi
from
Tacoma, WA
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
CAMC Clinical Trials Center
mi
from
Charleston, WV
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
CAMC Clinical Trials Center
mi
from
Charleston, WV
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
Emory University
mi
from
Atlanta, GA
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
Mount Sinai Hosp
mi
from
New York, NY
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
Lankenau Medical Center
mi
from
Wynnewood, PA
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
Lankenau Medical Center
mi
from
Wynnewood, PA
Click here to add this to my saved trials
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated:  3/2/2017
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
PLATINUM Diversity
PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)
Status: Enrolling
Updated: 3/2/2017
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
Click here to add this to my saved trials
Accuracy of Peripheral Pulse Oximetry Versus Arterial Co-oximeter in Children With Cyanotic Heart Disease
Accuracy of Peripheral Pulse Oximetry Versus Arterial Co-oximeter in Children With Cyanotic Heart Disease
Status: Enrolling
Updated:  3/7/2017
Stanford Univ Med Ctr
mi
from
Stanford, CA
Accuracy of Peripheral Pulse Oximetry Versus Arterial Co-oximeter in Children With Cyanotic Heart Disease
Accuracy of Peripheral Pulse Oximetry Versus Arterial Co-oximeter in Children With Cyanotic Heart Disease
Status: Enrolling
Updated: 3/7/2017
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Mindfulness & Stress Management Study for Cardiac Patients
Mindfulness-Based Stress Reduction as an Adjunct Intervention to Cardiac Rehabilitation: A Pilot Study
Status: Enrolling
Updated:  3/13/2017
University of Minnesota Medical Center
mi
from
Minneapolsi, MN
Mindfulness & Stress Management Study for Cardiac Patients
Mindfulness-Based Stress Reduction as an Adjunct Intervention to Cardiac Rehabilitation: A Pilot Study
Status: Enrolling
Updated: 3/13/2017
University of Minnesota Medical Center
mi
from
Minneapolsi, MN
Click here to add this to my saved trials
Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes
Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes
Status: Enrolling
Updated:  3/14/2017
Children's Hospital Colorado
mi
from
Aurora, CO
Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes
Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes
Status: Enrolling
Updated: 3/14/2017
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes
Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes
Status: Enrolling
Updated:  3/14/2017
University of Colorado Hospital
mi
from
Aurora, CO
Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes
Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes
Status: Enrolling
Updated: 3/14/2017
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Miami, FL
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Pheonix, AZ
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Pheonix, AZ
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Tucson, AZ
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Arcadia, CA
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Arcadia, CA
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Bakersfield, CA
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Beverly Hills, CA
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Palm Desert, CA
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Palm Desert, CA
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Sacramento, CA
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Santa Ana, CA
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Santa Ana, CA
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Santa Barbara, CA
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Golden, CO
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Golden, CO
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Boynton Beach, FL
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Fort Lauderdale, FL
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Fort Myers, FL
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Bellevue, WA
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Bellevue, WA
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Sarasota, FL
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Stuart, FL
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Stuart, FL
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Winter Haven, FL
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Winter Haven, FL
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Baltimore, MD
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Jackson, MI
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Jackson, MI
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Omaha, NE
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Reno, NV
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Reno, NV
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Rochester, NY
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Charlotte, NC
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Cincinnati, OH
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Cleveland, OH
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials